Works matching IS 15257304 AND DT 2011 AND VI 12 AND IP 2
Results: 11
Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non-Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Clinical Lung Cancer Volume 12 Issue 2 Frontend.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 1
- By:
- Publication type:
- Article
Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non-Small-Cell Lung Cancer Pretreated With Non-Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 100, doi. 10.1016/j.cllc.2011.03.004
- By:
- Publication type:
- Article
Prognostic Impact of Angiogenic Markers in Non-Small-Cell Lung Cancer is Related to Tumor Size.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 106, doi. 10.1016/j.cllc.2011.03.005
- By:
- Publication type:
- Article
First- or Second-line Gefitinib Therapy in Unknown Epidermal Growth Factor Receptor Mutants of Non-Small-Cell Lung Cancer Patients Treated in Taiwan.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 116, doi. 10.1016/j.cllc.2011.03.006
- By:
- Publication type:
- Article
Baseline Levels and Decrease in Serum Soluble Intercellular Adhesion Molecule-1 During Chemotherapy Predict Objective Response and Survival in Patients Who Have Advanced Non-Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 131, doi. 10.1016/j.cllc.2011.03.009
- By:
- Publication type:
- Article
Preclinical Efficacy of Vascular Disrupting Agents in Non-Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 81, doi. 10.1016/j.cllc.2011.03.001
- By:
- Publication type:
- Article
Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010): Focus on Developmental Therapeutics Related to Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 94, doi. 10.1016/j.cllc.2011.03.003
- By:
- Publication type:
- Article
Phase I/II Trial of a COX-2 Inhibitor With Limited Field Radiation for Intermediate Prognosis Patients Who Have Locally Advanced Non-Small-Cell Lung Cancer: Radiation Therapy Oncology Group 0213.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 125, doi. 10.1016/j.cllc.2011.03.007
- By:
- Publication type:
- Article
Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non-Small-Cell Lung Cancer With the Absenc of Epidermal Growth Factor Receptor Mutations
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 138, doi. 10.1016/j.cllc.2011.03.008
- By:
- Publication type:
- Article
History of Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2011, v. 12, n. 2, p. 87, doi. 10.1016/j.cllc.2011.03.002
- By:
- Publication type:
- Article